Neuroblastoma-Derived TGF-β1 Modulates the Chemokine Receptor Repertoire of Human Resting NK Cells

Journal of Immunology

Volumn 190, Issue 10, 2013, Pages 5321-5328

  Castriconi, Roberta ^a   Dondero, Alessandra ^a   Bellora, Francesca ^a   Moretta, Lorenzo ^a,b   Castellano, Aurora ^c   Locatelli, Franco ^c,d   Corrias, Maria Valeria ^b   Moretta, Alessandro ^a   Bottino, Cristina ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA1; CCR7 PROTEIN, HUMAN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR1; CX3CR1 PROTEIN, HUMAN; CXCR3 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; NCR3 PROTEIN, HUMAN; RECOMBINANT PROTEIN; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOMODULATION; NATURAL KILLER CELL; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RECEPTOR DOWN REGULATION; TUMOR ESCAPE; UPREGULATION; BIOSYNTHESIS; CHILD; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE;

ANTIGENS, CD56; CELL LINE, TUMOR; CHILD; HUMANS; KILLER CELLS, NATURAL; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NEUROBLASTOMA; RECEPTORS, CCR7; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR3; RECEPTORS, CXCR4; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT PROTEINS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR ESCAPE; UP-REGULATION;

MLCS; MLOWN;

EID: 84877805245     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202693     Document Type: Article

References (44)

1. Moretta, L., F. Locatelli, D. Pende, S. Sivori, M. Falco, C. Bottino, M. C. Mingari, and A. Moretta. 2011. Human NK receptors: from the molecules to the therapy of high risk leukemias. FEBS Lett. 585: 1563-1567.
2. Ljunggren, H. G., and K. J. Malmberg. 2007. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7: 329-339.
3. Stojanovic, A., and A. Cerwenka. 2011. Natural killer cells and solid tumors. J. Innate Immun. 3: 355-364.
4. Terme, M., E. Ullrich, N. F. Delahaye, N. Chaput, and L. Zitvogel. 2008. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat. Immunol. 9: 486-494. (Pubitemid 351560517)
5. Castriconi, R., A. Dondero, M. V. Corrias, E. Lanino, D. Pende, L. Moretta, C. Bottino, and A. Moretta. 2004. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res. 64: 9180-9184. (Pubitemid 39665534)
6. Pende, D., C. Bottino, R. Castriconi, C. Cantoni, S. Marcenaro, P. Rivera, G. M. Spaggiari, A. Dondero, B. Carnemolla, N. Reymond, et al. 2005. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol. Immunol. 42: 463-469. (Pubitemid 39655955)
7. Carlsten, M., N. K. Bjorkstrom, H. Norell, Y. Bryceson, T. van Hall, B. C. Baumann, M. Hanson, K. Schedvins, R. Kiessling, H. G. Ljunggren, and K. J. Malmberg. 2007. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 67: 1317-1325.
8. Castriconi, R., A. Daga, A. Dondero, G. Zona, P. L. Poliani, A. Melotti, F. Griffero, D. Marubbi, R. Spaziante, F. Bellora, et al. 2009. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J. Immunol. 182: 3530-3539.
9. Bottino, C., R. Castriconi, L. Moretta, and A. Moretta. 2005. Cellular ligands of activating NK receptors. Trends Immunol. 26: 221-226. (Pubitemid 41556860)
10. Garrido, F., F. Ruiz-Cabello, T. Cabrera, J. J. Pérez-Villar, M. López-Botet, M. Duggan-Keen, and P. L. Stern. 1997. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18: 89-95. (Pubitemid 27107103)
11. Walzer, T., and E. Vivier. 2011. G-protein-coupled receptors in control of natural killer cell migration. Trends Immunol. 32: 486-492.
12. Bellora, F., R. Castriconi, A. Dondero, G. Reggiardo, L. Moretta, A. Mantovani, A. Moretta, and C. Bottino. 2010. The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. Proc. Natl. Acad. Sci. USA 107: 21659-21664.
13. Groh, V., J. Wu, C. Yee, and T. Spies. 2002. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738. (Pubitemid 35177960)
14. Repp, A. C., E. S. Mayhew, S. Apte, and J. Y. Niederkorn. 2000. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J. Immunol. 165: 710-715. (Pubitemid 30484736)
15. Kalinski, P. 2012. Regulation of immune responses by prostaglandin E2. J. Immunol. 188: 21-28.
16. Della Chiesa, M., S. Carlomagno, G. Frumento, M. Balsamo, C. Cantoni, R. Conte, L. Moretta, A. Moretta, and M. Vitale. 2006. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46-And NKG2D-Activating receptors and regulates NK-cell function. Blood 108: 4118-4125. (Pubitemid 44913283)
17. Castriconi, R., C. Cantoni, M. Della Chiesa, M. Vitale, E. Marcenaro, R. Conte, R. Biassoni, C. Bottino, L. Moretta, and A. Moretta. 2003. Transforming growth factor b1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. USA 100: 4120-4125. (Pubitemid 36418167)
18. Friese, M. A., J. Wischhusen, W. Wick, M. Weiler, G. Eisele, A. Steinle, and M. Weller. 2004. RNA interference targeting transforming growth factor-b enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. 64: 7596-7603. (Pubitemid 39372105)
19. Lee, J. C., K. M. Lee, D. W. Kim, and D. S. Heo. 2004. Elevated TGF-b1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 172: 7335-7340. (Pubitemid 38747593)
20. +T cells in glioma patients. Neuro-oncol. 12: 7-13.
21. Yang, L., Y. Pang, and H. L. Moses. 2010. TGF-b and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 31: 220-227.
22. Uhl, M., S. Aulwurm, J. Wischhusen, M. Weiler, J. Y. Ma, R. Almirez, R. Mangadu, Y. W. Liu, M. Platten, U. Herrlinger, et al. 2004. SD-208, a novel transforming growth factor b receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64: 7954-7961. (Pubitemid 39446929)
23. Villegas, F. R., S. Coca, V. G. Villarrubia, R. Jiménez, M. J. Chillón, J. Jareno, M. Zuil, and L. Callol. 2002. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 35: 23-28. (Pubitemid 34028087)
24. Ishigami, S., S. Natsugoe, K. Tokuda, A. Nakajo, X. Che, H. Iwashige, K. Aridome, S. Hokita, and T. Aikou. 2000. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88: 577-583. (Pubitemid 30056932)
25. Carrega, P., B. Morandi, R. Costa, G. Frumento, G. Forte, G. Altavilla, G. B. Ratto, M. C. Mingari, L. Moretta, and G. Ferlazzo. 2008. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56bright CD162 cells and display an impaired capability to kill tumor cells. Cancer 112: 863-875. (Pubitemid 351240580)
26. Halama, N., M. Braun, C. Kahlert, A. Spille, C. Quack, N. Rahbari, M. Koch, J. Weitz, M. Kloor, I. Zoernig, et al. 2011. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin. Cancer Res. 17: 678-689.
27. Cooper, M. A., T. A. Fehniger, and M. A. Caligiuri. 2001. The biology of human natural killer-cell subsets. Trends Immunol. 22: 633-640. (Pubitemid 33043908)
28. +NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J. Immunol. 166: 6477-6482. (Pubitemid 32467184)
29. Beider, K., A. Nagler, O. Wald, S. Franitza, M. Dagan-Berger, H. Wald, H. Giladi, S. Brocke, J. Hanna, O. Mandelboim, et al. 2003. Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood 102: 1951-1958. (Pubitemid 37122366)
30. Noda, M., Y. Omatsu, T. Sugiyama, S. Oishi, N. Fujii, and T. Nagasawa. 2011. CXCL12-CXCR4 chemokine signaling is essential for NK-cell development in adult mice. Blood 117: 451-458.
31. Mayol, K., V. Biajoux, J. Marvel, K. Balabanian, and T.Walzer. 2011. Sequential desensitization of CXCR4 and S1P5 controls natural killer cell trafficking. Blood 118: 4863-4871.
32. Bernardini, G., G. Sciume, D. Bosisio, S. Morrone, S. Sozzani, and A. Santoni. 2008. CCL3 and CXCL12 regulate trafficking of mouse bone marrow NK cell subsets. Blood 111: 3626-3634.
33. +mouse NK-cell subsets with distinct functional properties and positioning in the bone marrow. Blood 117: 4467-4475.
34. Brodeur, G. M. 2003. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 3: 203-216. (Pubitemid 37328872)
35. Castriconi, R., A. Dondero, M. Cilli, E. Ognio, A. Pezzolo, B. De Giovanni, C. Gambini, V. Pistoia, L. Moretta, A. Moretta, and M. V. Corrias. 2007. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice. Cancer Immunol. Immunother. 56: 1733-1742. (Pubitemid 47313078)
36. Bogenmann, E. 1996. A metastatic neuroblastoma model in SCID mice. Int. J. Cancer 67: 379-385. (Pubitemid 26274129)
37. Longo, L., H. Christiansen, N. M. Christiansen, P. Cornaglia-Ferraris, and F. Lampert. 1988. N-myc amplification at chromosome band 1p32 in neuroblastoma cells as investigated by in situ hybridization. J. Cancer Res. Clin. Oncol. 114: 636-640. (Pubitemid 19011683)
38. Castriconi, R., A. Dondero, R. Augugliaro, C. Cantoni, B. Carnemolla, A. R. Sementa, F. Negri, R. Conte, M. V. Corrias, L. Moretta, et al. 2004. Identification of 4Ig-B7-H3 as a neuroblastoma-Associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc. Natl. Acad. Sci. USA 101: 12640-12645. (Pubitemid 39122076)
39. Inngjerdingen, M., B. Damaj, and A. A. Maghazachi. 2001. Expression and regulation of chemokine receptors in human natural killer cells. Blood 97: 367-375. (Pubitemid 32060319)
40. Blobe, G. C., W. P. Schiemann, and H. F. Lodish. 2000. Role of transforming growth factor beta in human disease. N. Engl. J. Med. 342: 1350-1358. (Pubitemid 30408720)
41. +cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J. Immunol. 168: 6173-6180. (Pubitemid 34620036)
42. Yoneda, O., T. Imai, S. Goda, H. Inoue, A. Yamauchi, T. Okazaki, H. Imai, O. Yoshie, E. T. Bloom, N. Domae, and H. Umehara. 2000. Fractalkine-mediated endothelial cell injury by NK cells. J. Immunol. 164: 4055-4062. (Pubitemid 30215060)
43. Domanska, U. M., R. C. Kruizinga, W. B. Nagengast, H. Timmer-Bosscha, G. Huls, E. G. de Vries, and A. M. Walenkamp. 2013. A review on CXCR4/ CXCL12 axis in oncology: no place to hide. Eur. J. Cancer 49: 219-230.
44. Worthington, J. J., J. E. Klementowicz, and M. A. Travis. 2011. TGFb: a sleeping giant awoken by integrins. Trends Biochem. Sci. 36: 47-54.